N-(6-氟-吡啶-2-基)-乙酰胺 | 258343-71-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-(6-氟-吡啶-2-基)-乙酰胺
• 英文名称: N-(6-fluoropyridin-2-yl)acetamide
• CAS: 258343-71-4
• 化学式: C₇H₇FN₂O
• 分子量: 154.144
• InChiKey: TYJSZNSMFKWJTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(6-氟-吡啶-2-基)-乙酰胺 在 硫酸 作用下， 反应 4.0h， 以70%的产率得到2-氨基-6-氟吡啶
  参考文献：
  名称：

  β-酮羧酸酯取代的2-氨基吡啶的缩合反应：4 H-吡啶[1,2- a ]嘧啶-4-酮和吡啶-2-酮

  摘要：

  我们报道了在多磷酸中β-酮羧酸酯与2-氨基吡啶5的缩合反应。在该反应中，与目标化合物一起获得了4 H-吡啶并[1,2- a ]嘧啶-4-酮6和吡啶-2-酮7。测试所有化合物7的钙拮抗活性，但未能引起任何血管舒张反应。

  DOI：

  10.1002/jhet.5570360502
• 作为产物：
  描述：

  N-乙酰基-1,6-二氨基吡啶 在 tetrafluoroboric acid 、 sodium nitrite 作用下， 反应 1.0h， 以61%的产率得到N-(6-氟-吡啶-2-基)-乙酰胺
  参考文献：
  名称：

  β-酮羧酸酯取代的2-氨基吡啶的缩合反应：4 H-吡啶[1,2- a ]嘧啶-4-酮和吡啶-2-酮

  摘要：

  我们报道了在多磷酸中β-酮羧酸酯与2-氨基吡啶5的缩合反应。在该反应中，与目标化合物一起获得了4 H-吡啶并[1,2- a ]嘧啶-4-酮6和吡啶-2-酮7。测试所有化合物7的钙拮抗活性，但未能引起任何血管舒张反应。

  DOI：

  10.1002/jhet.5570360502

文献信息

• Access to 2-pyridinylamide and imidazopyridine from 2-fluoropyridine and amidine hydrochloride
  作者：Yibiao Li、Shuo Huang、Jiaming Li、Jian Li、Xiaoliang Ji、Jiasheng Liu、Lu Chen、Shiyong Peng、Kun Zhang

  DOI：10.1039/d0ob01904f

  日期：——

  Under catalyst-free conditions, an efficient method to synthesize 2-pyridinylamides has been developed, and the protocol uses inexpensive and readily available 2-fluoropyridine and amidine derivatives as the starting materials. Simultaneously, the copper-catalysed approach to imidazopyridine derivatives has been established with high chemoselectivity and regiospecificity. The results suggest that the

  在无催化剂条件下，开发了一种合成 2-吡啶酰胺的有效方法，该协议使用廉价且易于获得的 2-氟吡啶和脒衍生物作为起始材料。同时，铜催化的咪唑并吡啶衍生物方法已被建立，具有高化学选择性和区域特异性。结果表明，含有碘化物取代基的氮杂环也可以通过级联Ullmann型偶联与反应相容，并且亲核取代反应以一锅方式提供目标产物。
• [EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA REPLICATION DU VIRUS DE L'IMMUNODEFICIENCE HUMAINE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010130034A1

  公开（公告）日：2010-11-18

  Compounds of formula I wherein a, R1, R2, R3, R4, R5 and R6 are defined herein, are useful as inhibitors of HIV replication.

  式I中的化合物，其中a、R1、R2、R3、R4、R5和R6如本文所定义，可用作HIV复制抑制剂。
• Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase
  申请人：Birch Martin Alan

  公开号：US20050131015A1

  公开（公告）日：2005-06-16

  Heterocyclic amides of formula (1) wherein: X is N or CH; R 4 and R 5 together are either —S—C(R 6 )═C(R 7 )— or —C(R 7 )═C(R 6 )—S—; R 6 and R 7 are independently selected from, for example hydrogen, halo and C l-4 alkyl; A is phenylene or heteroarylene; n is 0, 1 or 2; R 1 is selected from for example halo, nitro, cyano, hydroxy, carboxy; R 2 is hydrogen, hydroxy or carboxy; R 3 is selected from for example hydrogen, hydroxy, aryl, heterocyclyl and C 1-4 alkyl(optionally substituted by 1 or 2 R 8 groups); R 8 is selected from for example hydroxy, —COCOOR 9 , —C(O)N(R 9 )(R 10 ), —NHC(O)R 9 , (R 9 )(R 10 )N— and —COOR 9 ; R 9 and R 10 are selected from for example hydrogen, hydroxy, C 1-4 alkyl (optionally substituted by 1 or 2 R 13 ); R 13 is selected from hydroxy, halo, trihalomethyl and C 1-4 alkoxy; or a pharmaceutically acceptable salt or pro-drug thereof; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.

  公式（1）的杂环酰胺，其中：X是N或CH；R4和R5一起是—S—C(R6)═C(R7)—或—C(R7)═C(R6)—S—；R6和R7独立选择自氢、卤素和Cl-4烷基；A是苯基或杂环芳基；n为0、1或2；R1选择自卤素、硝基、氰基、羟基、羧基；R2是氢、羟基或羧基；R3选择自氢、羟基、芳基、杂环芳基和C1-4烷基（可选地取代1或2个R8基）；R8选择自羟基、—COCOOR9、—C（O）N（R9）（R10）、—NHC（O）R9、（R9）（R10）N—和—COOR9；R9和R10选择自氢、羟基、C1-4烷基（可选地取代1或2个R13）；R13选择自羟基、卤素、三卤甲基和C1-4烷氧基；或其药学上可接受的盐或前药；具有糖原磷酸化酶抑制活性，因此在治疗与增加的糖原磷酸化酶活性相关的疾病状态中具有价值。还描述了制造该杂环酰胺衍生物的过程以及含有它们的制药组合物。
• Chemical compounds
  申请人：Birch Martin Alan

  公开号：US20050131016A1

  公开（公告）日：2005-06-16

  Heterocyclic amides of formula (1) wherein: is a single or double bond; A is phenylene or heteroarylene; m is 0, 1 or 2; n is 0, 1 or 2; R 1 is selected from for example halo, nitro, cyano, hydroxy, carboxy; R 2 is hydrogen, hydroxy or carboxy; R 3 is selected from for example hydrogen, hydroxy, aryl, heterocyclyl and C 1-4 alkyl(optionally substituted by 1 or 2 R 8 groups); R 4 is independently selected from for example hydrogen, halo, nitro, cyano, hydroxy, C 1-4 alkyl, and C 1-4 alkanoyl; R 8 is selected from for example hydroxy, —COCOOR 9 , —C(O)N(R 9 )(R 10 ), —NHC(O)R 9 , (R 9 )(R 10 )N— and —COOR 9 ; R 9 and R 10 are selected from for example hydrogen, hydroxy, C 1-4 alkyl (optionally substituted by 1 or 2 R 13 ); R 13 is selected from hydroxy, halo, trihalomethyl and C 1-4 alkoxy; or a pharmaceutically acceptable salt or pro-drug thereof; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.

  化学式（1）中的杂环酰胺，其中：为单键或双键；A为苯基或杂环基；m为0、1或2；n为0、1或2；R1选自例如卤素、硝基、氰基、羟基、羧基；R2为氢、羟基或羧基；R3选自例如氢、羟基、芳基、杂环基和C1-4烷基（可选地被1或2个R8基取代）；R4独立选自例如氢、卤素、硝基、氰基、羟基、C1-4烷基和C1-4烷酰基；R8选自例如羟基、—COCOOR9、—C（O）N（R9）（R10）、—NHC（O）R9、（R9）（R10）N—和—COOR9；R9和R10选自例如氢、羟基、C1-4烷基（可选地被1或2个R13取代）；R13选自羟基、卤素、三卤甲基和C1-4烷氧基；或其药学上可接受的盐或前药；具有糖原磷酸化酶抑制活性，因此对治疗与增加的糖原磷酸化酶活性相关的疾病状态具有价值。描述了制备所述杂环酰胺衍生物的工艺和含有它们的药物组成物。
• HETEROCYCLIC AMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE
  申请人：Birch Martin Alan

  公开号：US20070043069A1

  公开（公告）日：2007-02-22

  Heterocyclic amides of formula (1) wherein: X is N or CH; R 4 and R 5 together are either —S—C(R 6 )═C(R 7 )— or —C(R 7 )═C(R 6 )—S—; R 6 and R 7 are independently selected from, for example hydrogen, halo and C 1-4 alkyl; A is phenylene or heteroarylene; n is 0, 1 or 2; R 1 is selected from for example halo, nitro, cyano, hydroxy, carboxy; R 2 is hydrogen, hydroxy or carboxy; R 3 is selected from for example hydrogen, hydroxy, aryl, heterocyclyl and C 1-4 alkyl(optionally substituted by 1 or 2 R 8 groups); R 8 is selected from for example hydroxy, —COCOOR 9 , —C(O)N(R 9 )(R 10 ), —NHC(O)R 9 , (R 9 )(R 10 )N— and —COOR 9 ; R 9 and R 10 are selected from for example hydrogen, hydroxy, C 1-4 alkyl (optionally substituted by 1 or 2 R 13 ); R 13 is selected from hydroxy, halo, trihalomethyl and C 1-4 alkoxy; or a pharmaceutically acceptable salt or pro-drug thereof, possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.

  式（1）的杂环酰胺，其中：X为N或CH；R4和R5组合在一起是—S—C(R6)═C(R7)—或—C(R7)═C(R6)—S—；R6和R7独立选择自例如氢、卤素和C1-4烷基；A为苯撑或杂芳撑；n为0、1或2；R1选择自例如卤素、硝基、氰基、羟基、羧基；R2为氢、羟基或羧基；R3选择自例如氢、羟基、芳基、杂环基和C1-4烷基（可以选择性地被1或2个R8基取代）；R8选择自例如羟基、—COCOOR9、—C(O)N(R9)(R10)、—NHC(O)R9、(R9)(R10)N—和—COOR9；R9和R10选择自例如氢、羟基、C1-4烷基（可以选择性地被1或2个R13取代）；R13选择自羟基、卤素、三卤甲基和C1-4烷氧基；或其药学上可接受的盐或前药具有糖原磷酸化酶抑制活性，因此在治疗与增加的糖原磷酸化酶活性相关的疾病状态方面具有价值。描述了制备该杂环酰胺衍生物的方法和含有它们的药物组合物。